Octreotide Acetate Patent Expiration
Octreotide Acetate was first introduced by Novartis Pharmaceuticals Corp
Octreotide Acetate Patents
Given below is the list of patents protecting Octreotide Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bynfezia Pen | US12350475 | Method Of Injecting Octreotide Acetate Into The Body | Dec 29, 2041 | Sun Pharm |
| Mycapssa | US11141457 | Oral octreotide therapy and contraceptive methods | Dec 28, 2040 | Chiesi |
| Mycapssa | US11890316 | Oral octreotide therapy and contraceptive methods | Dec 28, 2040 | Chiesi |
| Bynfezia Pen | US11052196 | Method of injecting octreotide acetate into the body | Nov 03, 2040 | Sun Pharm |
| Bynfezia Pen | US11246991 | Electrolysis-resistant coupling assembly for valves | Nov 03, 2040 | Sun Pharm |
| Bynfezia Pen | US11534553 | Method of injecting octreotide acetate into the body | Nov 03, 2040 | Sun Pharm |
| Bynfezia Pen | US10342850 | Octreotide injection | May 15, 2038 | Sun Pharm |
| Mycapssa | US10238709 | Method of treating diseases | Feb 03, 2036 | Chiesi |
| Mycapssa | US10695397 | Method of treating diseases | Feb 03, 2036 | Chiesi |
| Mycapssa | US11052126 | Method of treating diseases | Feb 03, 2036 | Chiesi |
| Mycapssa | US11338011 | Method of treating diseases | Feb 03, 2036 | Chiesi |
| Mycapssa | US11510963 | Method of treating diseases | Feb 03, 2036 | Chiesi |
| Mycapssa | US11857595 | Method of treating diseases | Feb 03, 2036 | Chiesi |
| Mycapssa | US12246054 | Method of treating diseases | Feb 03, 2036 | Chiesi |
| Mycapssa | US12251418 | Method of treating diseases | Feb 03, 2036 | Chiesi |
| Mycapssa | US11969471 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
| Mycapssa | US11986529 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
| Mycapssa | US8329198 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
| Mycapssa | US8535695 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
| Mycapssa | US9265812 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
| Mycapssa | US9566246 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
| Sandostatin Lar |
US5922338 (Pediatric) | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan 13, 2017
(Expired) | Novartis |
| Sandostatin Lar |
US5922682 (Pediatric) | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan 13, 2017
(Expired) | Novartis |
| Sandostatin Lar | US5922338 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul 13, 2016
(Expired) | Novartis |
| Sandostatin Lar | US5922682 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul 13, 2016
(Expired) | Novartis |
| Sandostatin |
US5753618 (Pediatric) | Somatostatin analogue composition and use in treating breast cancer |
Nov 19, 2015
(Expired) | Novartis |
| Sandostatin | US5753618 | Somatostatin analogue composition and use in treating breast cancer |
May 19, 2015
(Expired) | Novartis |
| Sandostatin Lar |
US5688530 (Pediatric) | Sustained release formulations of water soluble peptides |
May 18, 2015
(Expired) | Novartis |
| Sandostatin Lar |
US5639480 (Pediatric) | Sustained release formulations of water soluble peptides |
Dec 17, 2014
(Expired) | Novartis |
| Sandostatin Lar | US5688530 | Sustained release formulations of water soluble peptides |
Nov 18, 2014
(Expired) | Novartis |
| Sandostatin Lar | US5639480 | Sustained release formulations of water soluble peptides |
Jun 17, 2014
(Expired) | Novartis |
| Sandostatin Lar |
US5538739 (Pediatric) | Sustained release formulations of water soluble peptides |
Jan 23, 2014
(Expired) | Novartis |
| Sandostatin Lar | US5538739 | Sustained release formulations of water soluble peptides |
Jul 23, 2013
(Expired) | Novartis |
Octreotide Acetate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Octreotide Acetate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | National Cancer Institute (NCI) | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |